Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Mucosal vaccines against respiratory syncytial virus.

Literature DB >> 24794644

Mucosal vaccines against respiratory syncytial virus.

Abstract

Respiratory syncytial virus (RSV) is a leading cause of severe respiratory disease in infants, young children, immune-compromised and elderly populations worldwide. Natural RSV infection in young children does not elicit long-lasting immunity and individuals remain susceptible to repeated RSV infections throughout life. Because RSV infection is restricted to the respiratory tract, an RSV vaccine should elicit mucosal immunity at upper and lower respiratory tracts in order to most effectively prevent RSV reinfection. Although there is no safe and effective RSV vaccine available, significant progress has been recently made in basic RSV research and vaccine development. This review will discuss recent advances in the identification of a new neutralizing antigenic site within the RSV fusion (F) protein, understanding the importance of mucosal immune responses against RSV infection, and the development of novel mucosal vaccination strategies.

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2014 PMID： 24794644 PMCID： PMC4079457 DOI： 10.1016/j.coviro.2014.03.009

Source DB: PubMed Journal: Curr Opin Virol ISSN： 1879-6257 Impact factor: 7.090

56 in total

1. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.

Authors: Michael Vaine; Shixia Wang; Anthony Hackett; James Arthos; Shan Lu
Journal: Vaccine Date: 2010-02-17 Impact factor: 3.641

2. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus.

Authors: Jason S McLellan; Man Chen; M Gordon Joyce; Mallika Sastry; Guillaume B E Stewart-Jones; Yongping Yang; Baoshan Zhang; Lei Chen; Sanjay Srivatsan; Anqi Zheng; Tongqing Zhou; Kevin W Graepel; Azad Kumar; Syed Moin; Jeffrey C Boyington; Gwo-Yu Chuang; Cinque Soto; Ulrich Baxa; Arjen Q Bakker; Hergen Spits; Tim Beaumont; Zizheng Zheng; Ningshao Xia; Sung-Youl Ko; John-Paul Todd; Srinivas Rao; Barney S Graham; Peter D Kwong
Journal: Science Date: 2013-11-01 Impact factor: 47.728

3. A mucosal vaccination approach for herpes simplex virus type 2.

Authors: Rebecca S Tirabassi; Christopher I Ace; Tatyana Levchenko; Vladimir P Torchilin; Liisa K Selin; Siwei Nie; Dennis L Guberski; Kejian Yang
Journal: Vaccine Date: 2010-12-04 Impact factor: 3.641

4. Soluble respiratory syncytial virus fusion protein in the fully cleaved, pretriggered state is triggered by exposure to low-molarity buffer.

Authors: Supranee Chaiwatpongsakorn; Raquel F Epand; Peter L Collins; Richard M Epand; Mark E Peeples
Journal: J Virol Date: 2011-02-09 Impact factor: 5.103

5. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention.

Authors: Margarita Magro; Vicente Mas; Keith Chappell; Mónica Vázquez; Olga Cano; Daniel Luque; María C Terrón; José A Melero; Concepción Palomo
Journal: Proc Natl Acad Sci U S A Date: 2012-02-08 Impact factor: 11.205

6. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals.

Authors: Ann R Falsey; Edward E Walsh; Jose Capellan; Stefan Gravenstein; Maria Zambon; Eddy Yau; Geoffrey J Gorse; Robert Edelman; Frederick G Hayden; Janet E McElhaney; Kathleen M Neuzil; Kristen L Nichol; Eric A F Simões; Peter F Wright; Valérie M-P Sales
Journal: J Infect Dis Date: 2008-11-01 Impact factor: 5.226

7. Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies.

Authors: Michael Vaine; Shixia Wang; Qin Liu; James Arthos; David Montefiori; Paul Goepfert; M Juliana McElrath; Shan Lu
Journal: PLoS One Date: 2010-11-09 Impact factor: 3.240

Review 8. Respiratory syncytial virus vaccine development.

Authors: Larry J Anderson
Journal: Semin Immunol Date: 2013-06-15 Impact factor: 11.130

9. Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination.

Authors: Michael Vaine; Shixia Wang; Emma T Crooks; Pengfei Jiang; David C Montefiori; James Binley; Shan Lu
Journal: J Virol Date: 2008-05-21 Impact factor: 5.103

Review 10. Challenges in developing a pediatric RSV vaccine.

Authors: Jeanne H Schickli; Filip Dubovsky; Roderick S Tang
Journal: Hum Vaccin Date: 2009-09-28

7 in total

1. Respiratory Syncytial Virus (RSV) Pulmonary Infection in Humanized Mice Induces Human Anti-RSV Immune Responses and Pathology.

Authors: Anurag Sharma; Wenzhu Wu; Biin Sung; Jing Huang; Tiffany Tsao; Xiangming Li; Rika Gomi; Moriya Tsuji; Stefan Worgall
Journal: J Virol Date: 2016-04-29 Impact factor: 5.103

Mucosal vaccines against respiratory syncytial virus.

1. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.

2. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus.

3. A mucosal vaccination approach for herpes simplex virus type 2.

4. Soluble respiratory syncytial virus fusion protein in the fully cleaved, pretriggered state is triggered by exposure to low-molarity buffer.

5. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention.

6. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals.

7. Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies.

Review 8. Respiratory syncytial virus vaccine development.

9. Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination.

Review 10. Challenges in developing a pediatric RSV vaccine.

1. Respiratory Syncytial Virus (RSV) Pulmonary Infection in Humanized Mice Induces Human Anti-RSV Immune Responses and Pathology.

Review 2. Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses.

Review 3. Neonatal Immunization: Rationale, Current State, and Future Prospects.

4. Systematic comparison of respiratory syncytial virus-induced memory B cell responses in two anatomical compartments.

Review 5. Promising approaches for the treatment and prevention of viral respiratory illnesses.

Review 6. Respiratory nanoparticle-based vaccines and challenges associated with animal models and translation.

7. Current Insights in the Development of Efficacious Vaccines Against RSV.